Role of Pentoxifylline and Celecoxib in Parkinsonism

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 7, 2023

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions
Parkinson Disease
Interventions
DRUG

carbidopa-levodopa

Levodopa is typically prescribed to a patient with Parkinson disease once symptoms become more difficult to control with other anti-parkinsonism drugs. The drug can also be used for postencephalitic parkinsonism and symptomatic parkinsonism due to carbon monoxide intoxication

DRUG

Pentoxifylline 400 MG

Pentoxifylline (PTX) has a well validated immune modulatory and anti-inflammatory efficacy via suppression of the TLR4/NF-κB network signaling pathway. Moreover, Pentoxifylline has a potential antioxidant capacity mostly via nuclear erythroid 2-related factor 2 (Nrf2) activation with subsequent up-regulation and expression of several antioxidant enzymes

DRUG

Celecoxib 200mg

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis

Trial Locations (1)

35511

Faculty of Medicine, Mansoura University, Al Mansurah

All Listed Sponsors
collaborator

Tanta University

OTHER

collaborator

Mohanad Omar Khrieba Clinical Pharmacy Department, Faculty of Pharmacy - Horus University

UNKNOWN

lead

Mostafa Bahaa

OTHER